Fareston
INDICATIONS
FARESTON is indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors.
DOSAGE AND ADMINISTRATION
The dosage of FARESTON is 60 mg, once daily, orally. Treatment is generally continued until disease progression is observed.
HOW SUPPLIED
FARESTON Tablets, containing toremifene citrate in an amount equivalent to 60 mg of toremifene, are round, convex, unscored, uncoated, and white, or almost white.
FARESTON Tablets are identified with TO 60 embossed on one side.
FARESTON Tablets are available as:
NDC 54092-170-30 bottles of 30
NDC 54092-170-01 bottles of 100
Store at 25°C (77°F) excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].
Protect from heat and light.
Developed and Manufactured by
Orion Corporation, Espoo, Finland
Distributed by Shire US Inc.
Newport, KY 41071, USA
under license from Orion Corporation.
Product covered by Orion Product Patents and related patent numbers.
© 2001 Shire US Inc.
All rights reserved.
Generic Name: Toremifene
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Breast Cancer
Find support and advances in treatment.
Cancer and Exercise
Resting to conserve energy may not be the best remedy for fatigue during radiation therapy. See more WebMD Videos »
Fareston
Health Resources
2008 Election & Health Care on WebMD. Get Informed.
Updated & New
RxList does not provide medical advice, diagnosis or treatment.